29
Oversold
Moving averages
SMA 200$1.48-52.52%
Company profile
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern, Pennsylvania.
SectorHealthcare
IndustryBiotechnology
Market cap$321.21M
P/E ratioNone
EPS$-0.26
Beta2.268
Dividend yield0.00%
52-week high$2.73
52-week low$0.87
Similar stocks in Biotechnology
BNTX
BioNTech SE
RSI 41
VRTX
Vertex Pharmaceuticals Inc
RSI 68
CRSP
CRISPR Therapeutics AG
RSI 48
IOVA
Iovance Biotherapeutics Inc
RSI 30
ARTV
Artiva Biotherapeutics Inc
RSI 21
AGEN
Agenus Inc
RSI 47
ARCT
Arcturus Therapeutics Holdings Inc
RSI 45
EDIT
Editas Medicine Inc
RSI 51
CAPR
Capricor Therapeutics Inc
RSI 42
TRDA
Entrada Therapeutics Inc
RSI 41
RSI alerts for OCGN
An email when OCGN closes below RSI 30 or above 70. Nothing else.
Add alertData last updated 13 October 2026 at 10:29 PM EDT